Extended Data Fig. 4: T-M@eOA therapy reshapes immunosuppressive TME in vivo.
From: An oncolytic virus–T cell chimera for cancer immunotherapy
a, Cytometry plots and the quantitative analysis of eOA-Cy7 in TCR Vα2+ carrier T cells in blood 6 h after i.v. injection. b, Quantitative analysis of organ distribution of Cy7-eOA and carrier DiD-OT-1 CD8+ T cells 24 h after i.v. administration in different organs. c, CLSM images of tumor sections after i.v. administration of T + M@eOA or T-M@eOA for 24 h. eOA were labeled by Cy7, and carrier T cells were labeled by DiD. Scale bar 200 μm. d, Representative B16OVA tumor section imaging after T-M@eOA-GFP treatment for 72 h. GFP expression was indicated in the eOA-GFP-infected cells (left). Blue signal, DAPI. Scale bar 300 μm. Quantitative analysis of GFP expression after eOA-GFP infection (right), n = 5 biological independent samples. e, Indel mutations of PDL1 locus in tumor after indicated treatments (upper), and different organs after T-M@eOA treatment (lower). f, Quantitative analysis of PDL1 expression in different type of cells. n = 5 biological independent mice. g, Gating strategy for the PDL1 expression in different subpopulations. Plots are representative of six experimental replicates. Data are presented as mean ± s.d. Paired two-tailed t-test was used in (a), one-way ANOVA with Tukey’s post hoc test was used in (f), with P values indicated on the graphs. NS denotes no significant difference (P > 0.05).
